Lv1
62 积分 2024-12-13 加入
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
15小时前
待确认
Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase
16小时前
已完结
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
16小时前
已完结
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
1天前
已完结
Process Development and GMP Production of a Potent NAE Inhibitor Pevonedistat
17天前
已完结
Development of an Efficient Manufacturing Process for Reversible Bruton’s Tyrosine Kinase Inhibitor GDC-0853
17天前
已完结
Targeting BTK in CLL: Beyond Ibrutinib
23天前
已完结
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
23天前
已完结
Practical Synthesis of 6-Amino-1-hydroxy-2,1-benzoxaborolane: A Key Intermediate of DNDI-6148
29天前
已完结
Large Scale Deprotection of a tert-Butoxycarbonyl (Boc) Group Using Aqueous HCl and Acetone
1个月前
已完结
皖公网安备34019202002308
